We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current NAMS market cap is 2.42B. The company's latest EPS is USD -1.9152 and P/E is -13.60.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | |||||
| Total Revenue | 2.94M | 803k | 1.4M | 2.28M | 29.11M |
| Operating Income | -49.56M | -50.79M | -55.48M | -52.58M | -25M |
| Net Income | -47.13M | -49.5M | -93.77M | -39.01M | -16.65M |
| Year End 31 December 2023 | 2023 |
|---|---|
| USD (US$) | |
| Total Revenue | 14.09M |
| Operating Income | -182.69M |
| Net Income | -176.94M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | |||||
| Total Assets | 0 | 347.1M | 488.46M | 446.69M | 439.19M |
| Total Liabilities | 0 | 58.7M | 76.66M | 59.25M | 60.33M |
| Total Equity | 0 | 288.39M | 411.8M | 387.44M | 378.86M |
| Year End 31 December 2023 | 2023 |
|---|---|
| USD (US$) | |
| Total Assets | 347.1M |
| Total Liabilities | 58.7M |
| Total Equity | 288.39M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | |||||
| Operating | -108.14M | -141.22M | -54.6M | -108.58M | -121.08M |
| Investing | -21k | -24k | -385k | -594k | -669k |
| Financing | 8.91M | 8.91M | 198.18M | 202.84M | 202.9M |
| Year End 31 December 2023 | 2023 |
|---|---|
| USD (US$) | |
| Operating | -141.22M |
| Investing | -24k |
| Financing | 8.91M |
| Market Cap | 2.42B |
| Price to Earnings Ratio | -13.60 |
| Price to Sales Ratio | 170.75 |
| Price to Cash Ratio | 7.07 |
| Price to Book Ratio | 8.34 |
| Dividend Yield | - |
| Shares Outstanding | 92.39M |
| Average Volume (1 week) | 559.66k |
| Average Volume (1 Month) | 881.03k |
| 52 Week Change | 102.32% |
| 52 Week High | 26.95 |
| 52 Week Low | 11.95 |
| Spread (Intraday) | 0.07 (0.27%) |
| Company Name | NewAmsterdam Pharma Company NV |
| Address |
gooimeer 2-35 naarden, north holland 1411 DC |
| Website | https://www.newamsterdampharma.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
